DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Loncastuximab tesirine
Loncastuximab tesirine
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Draft Minutes PDCO 12-15 November 2019
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Antibody–Drug Conjugates
Antibody–Drug Conjugates: the Last Decade
5.01.582 Antibody-Drug Conjugates
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Loncastuximab Tesirine-Lpyl
Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma Brad S
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Treating Non-Hodgkin Lymphoma If You’Ve Been Diagnosed with Non-Hodgkin Lymphoma, Your Treatment Team Will Discuss Your Options with You
Antibody–Drug Conjugates for Cancer Therapy
View of This Manuscript
Loncastuximab Tesirine, an Anti-CD19 Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Malignant Hematology
Antibody–Drug Conjugates—A Tutorial Review
Loncastuximab Tesirine Clinical Assessments
The Oncology Market for Antibody–Drug Conjugates
Top View
ADC Therapeutics Appoints Joseph Camardo, MD, As Head of Medical Affairs
How I Treat Relapsed/Refractory Disease – DLBCL and CLL
Open Full Page
Specialty Injectables Prior Authorization List
Antibody–Drug Conjugates for Cancer Therapy
Diffuse Large B-Cell Lymphoma (DLBCL) Current Landscape and Challenges
Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: a Systematic Review
Oncology Medications Policy (1403)
New Agents and Regimens for Diffuse Large B Cell Lymphoma
SUMMARY of DRUG LIMITATIONS Medications Listed in This Document May Or May Not Require a Prior Authorization
Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
Clinical Policy: Loncastuximab Tesirine-Lpyl (Zynlonta)
Diffuse Large B-Cell Lymphoma: New Targets and Novel Therapies Bruce D
View Volume 2 Issue 2
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
FDA Updates Highlighting the Latest Cancer Treatments
PDF of Antibody News
Services That Require Precertification Standard Precert Effective: 7/1/2021 This Applies to Elective, Nonemergency Services